EBAMED ANNOUNCES FIRST PATIENT ENROLLED IN PROSPECTIVE IMAGING STUDY WITH ULTRASOUND GUIDANCE PROTOTYPE IN VENTRICULAR TACHYCARDIA PATIENTS

PAVIA, July 16, 2021 –EBAMed SA, an early-stage medical device company pioneering new approaches to proton therapy today announced the enrollment of the first patient in a prospective imaging study using a device that automatically interprets cardiac ultrasound images to uniquely track the motion of the heart.

The first patient was enrolled at the Policlinico San Matteo, Pavia (Italy). This important company milestone was reached according to development schedule. 

The main objectives of the study are to collect cardiac ultrasound data from patients diagnosed with ventricular tachycardia (VT). The investigators will analyze ultrasound image data quality and establish if it is adequate to support the development of an add-on medical device to guide proton-therapy systems currently used in oncology and adapt the technology to non-invasive treatment of cardiac arrhythmias. Such device would also include a gating signal generator to precisely gate treatment beams, which are delivered to the patients during radio-ablation procedures.

Robert Rordorf, MD, Chief of the Electrophysiology Unit of San Matteo Hospital, said: “Catheter ablation is the gold standard therapy for recurrent scar-related VT, but its efficiency is suboptimal. Proton therapy shows great promise due to its high-dose delivery capability, while minimizing the off-target dose. The challenge remains how to treat a beating heart. This research is testing a new promising technology to optimize compensation for cardiorespiratory movements”.

Marina Izzo, Chief Executive Officer of EBAMed, said: “Current ablation systems are inadequate to treat the thick ventricular tissue. At EBAMed our vision is to enable proton therapy for ventricular ablation. This powerful technology can generate efficient scars and abolish ventricular arrhythmias in less than 30 minutes.”

Ultrasound guidance has the potential to unleash the power of proton therapy for cardiac arrhythmia patients, filling an important unmet need. The development of a radiation therapy approach, combined with an unique motion monitoring and gating solution, could be of substantial value in providing alternative therapy to either drug therapy or catheter-based ablation, and to reduce radiation to innocent myocardium

WE ARE PRESENT THIS YEAR AT #AAPM2021AnnualMeeting with news about Ultrasound Image Guidance for Interventions. https://lnkd.in/eN8Xt7H

GENEVA, June 1 2021

INTERVIEW WITH EXPERTS: MARINA IZZO, CEO

GENEVA, March 18 2021 –Venture asked Marina Izzo about her experiences in the industry and her vision for EBAMed.

You can find the complete article at: https://lnkd.in/dMuseyw

EBAMED IS HIRING AN HARWARE ENGINEER AND A HEAD OF SOFTWARE ENGINEER

GENEVA, March 1 2021 –EBAMed SA is looking for key R&D positions to boost development efforts. It is a great opportunity to join a leading and fast growing innovative company in the field of non-invasive cardiac interventions providing top quality and top performing products to the market. #research&development #medical #hiring. To apply, please send an email to admin@eba-med.com

SWISS-BASED MEDTECH STARTUP EBAMED APPOINTS MARINA IZZO AS CEO

GENEVA, February 18 2021 –EBAMed SA, developer of medical technologies to transform the treatment of cardiac arrhythmias, has appointed experienced specialist Marina Izzo as Chief Executive Officer (CEO). Mrs. Izzo will set the vision for EBAMed’s technology and lead the effort for the next financing round, planned for 2022. Former CEO and co-founder, Adriano Garonna has transitioned to Chief Technology Officer (CTO) and maintains a role on the company’s Board of Directors. 

“Marina has strong experience in leading medical device businesses and developing the market for groundbreaking cardiovascular technologies in Europe, North America and China,” said Mr. Giovanni Leo, Chairman of the Board. “Her experience will be invaluable as we realize our mission to shift the paradigm in electrophysiology (EP) from catheter-based ablation therapies to non-invasive EP procedures.”

EBAMED IS AWARDED EUR 2.4 MILLION BY THE EUROPEAN UNION TO DEVELOP ITS CARDIAC MOTION MANAGEMENT PRODUCT FOR THE NON-INVASIVE TREATMENT OF HEART ARRHYTHMIAS

GENEVA, September 23, 2020 – EBAMed SA has been awarded EUR 2.4 million in a non-dilutive grant (agreement No. 954783) by the Enhanced European Innovation Council (EIC) to develop its cardiac motion management product for the non-invasive treatment of heart arrhythmias. The grant enables EBAMed to optimize the product’s hardware and software components

“The procedure is quick, safe, painless and suitable for any age and health condition patient with no side effects and we expect it will provide an efficient alternative to existing treatments,” states EBAMed’s co-founder, Prof. Ugo Amaldi (CERN). “EBAMed will work with several clinical institutions, such as the National Center of Oncological Hadron therapy CNAO in Italy and the University Hospital UZ Leuven in Belgium, in order to fine-tune the use of its technology.”

The Horizon2020 EIC pilot aims to support top-class innovators, start-ups, small companies and researchers with bright ideas that are radically different from existing products, services or business models, are highly risky and have the potential to scale up internationally. 

EBAMED JOINS THE MAYO CLINIC BUSINESS ACCELERATOR AND STARTS PRE CLINICAL TESTING

GENEVA, Switzerland, March 10, 2020 – _EBAMed SA is glad to announce its entry into the Mayo Clinic Business Accelerator located in Rochester, Minnesota, USA, in January 2020. This will allow EBAMed to work closely with Mayo Clinic on pre-clinical tests whilst ensuring a first presence in the United States.

EBAMED CLOSES CHF 1.2 MILLION SEED FINANCING TO ADVANCE NON-INVASIVE THERAPY FOR HEART ARRHYTHMIAS. FUNDING SUPPORTS DEVELOPMENT OF FIRST INTEGRATED HEART MOTION MANAGEMENT SYSTEM AND PRE-CLINICAL TESTING

GENEVA, August 21, 2019